TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›CME›Financials
Annual statements · SEC XBRL · FY2016 – FY2025

CME GROUP INC. (CME) financials

Income statement

CME GROUP INC. (CME) income statement, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$3.60B$3.64B$4.31B$4.87B$4.88B$4.69B$5.02B$5.58B$6.13B$6.52B
Revenue growth—1.4%18.2%13.0%0.3%-4.0%7.0%11.1%9.9%6.4%
Operating income$2.20B$2.31B$2.61B$2.59B$2.64B$2.65B$3.02B$3.44B$3.93B$4.23B
Operating margin61.2%63.4%60.5%53.2%54.0%56.4%60.1%61.6%64.1%64.9%
Net income$1.53B$4.06B$1.96B$2.12B$2.11B$2.64B$2.69B$3.23B$3.53B$4.07B
Net margin42.7%111.5%45.5%43.5%43.1%56.2%53.6%57.8%57.5%62.5%
EPS (diluted)$4.53$11.94$5.71$5.91$5.87$7.29$7.40$8.86$9.67$11.16

Cash flow

CME GROUP INC. (CME) cash flow, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$1.73B$1.75B$2.44B$2.67B$2.72B$2.40B$3.06B$3.45B$3.69B$4.28B
Capital expenditures$91.8M$81.9M$117M$246M$198M$127M$89.7M$76.4M$94.0M$83.5M
Free cash flow$1.64B$1.67B$2.32B$2.43B$2.52B$2.28B$2.97B$3.38B$3.60B$4.19B
Dividends paid$1.79B$1.99B$2.15B$1.70B$2.11B$2.19B$2.63B$3.24B$3.58B$3.93B

Balance sheet

CME GROUP INC. (CME) balance sheet, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$1.87B$1.90B$1.37B$1.55B$1.63B$2.83B$2.72B$2.91B$2.89B$4.42B
Total assets$69.4B$75.8B$77.5B$75.2B$125B$197B$174B$130B$137B$198B
Total liabilities$49.0B$53.4B$51.5B$49.1B$98.3B$169B$147B$103B$111B$170B
Shareholders' equity$20.3B$22.4B$25.9B$26.1B$26.3B$27.4B$26.9B$26.7B$26.5B$28.7B
Retained earnings$2.52B$4.50B$4.86B$5.01B$5.00B$5.15B$4.75B$4.46B$4.19B$6.43B
Shares (wtd avg diluted)339M340M344M358M359M359M359M360M360M360M

Every figure is extracted from CME GROUP INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is CME GROUP INC.'s annual revenue?
CME GROUP INC. (CME) reported $6.52B of revenue for fiscal year 2025 — up 6.4% from $6.13B in FY2024, per its annual report filed with the SEC.
Is CME GROUP INC. profitable?
Yes — CME earned $4.07B of net income in FY2025, a 62.5% net margin, per SEC filings.
What is CME GROUP INC.'s free cash flow?
$4.19B in FY2025 (operating cash flow $4.28B minus $83.5M of capital expenditures), from the SEC cash-flow statement.
Does CME pay a dividend?
Yes — CME GROUP INC. paid $3.93B in cash dividends during FY2025, per its SEC cash-flow statement.
Full CME analysis — verdict, score & filings →Is CME a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.